Health and Healthcare
FDA Complete Response Letter Takes a Big Bite Out of Hope (SLXP, PGNX)
Published:
Last Updated:
The U.S. Food & Drug Administration has sent Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) a Complete Response Letter (CRL) regarding the drug Relistor’s supplemental new drug application. Relistor is an injection for subcutaneous use for the treatment of opioid-induced constipation in adult patients who suffer from chronic, noncancer pain.
The CRL is now requesting additional clinical data. Salix and Progenics said that they intend to request an End-of-Review meeting with the Division of Gastroenterology and Inborn Errors Products to better understand the contents of the CRL.
Unfortunately the news is crushing. Progenix shares are down almost 50% at $5.45 in very active trading. The market cap prior to the drop was $365 million.
Salix was worth just over $3 billion and its shares are indicated down about 15% at $44.99 after a $53.19 close on Friday. So far we have seen Cantor Fitzgerald and Susquehanna downgrade Salix.
As is usual with Complete Response Letters, this means delays and higher costs of approval. It also is often is far worse than just that.
JON C. OGG
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
